(S)-1-[4-[[2-(2-氨基嘧啶-5-基)-7-甲基-4-(吗啉-4-基)噻吩并[3,2-D]嘧啶-6-基]甲基]哌嗪-1-基]-2-羟基丙-1-酮性质、用途与生产工艺
GDC-0980 (RG7422)是一种有效的,I型PI3K抑制剂,作用于PI3Kα/β/δ/γ,IC50分别为5 nM/27 nM/7 nM/14 nM,也抑制mTOR,K
i为17 nM,高选择性作用于其他PIKK家族激酶。Phase 2。
GDC-0980 shows the potent and selective inhibitory activities against class I PI3K and mTOR kinase versus a large panel of kinases with K
i of 17 nM for mTOR and IC50 of 5 nM, 27 nM, 7 nM, and 14 nM for PI3Kα, β, δ, and γ, respectively. In vitro, GDC-0980 significantly inhibits cell proliferation in PC3 and MCF7 cells with IC50 of 307 nM and 255 nM, respectively. A recent study shows that GDC-0980 reduces cancer cell viability by inhibiting cell-cycle procession and inducing apoptosis with most potency in prostate (IC50 < 200 nM 50%), <500 nM 100%), breast (IC50 <200 nM 37%, <500 nM 78%) and NSCLC lines (IC50 <200 nM 29%, <500 nM 88%) and less potency in pancreatic (IC50 <200 nM 13%, <500 nM 67%) and melanoma cell lines (IC50 <200 nM 0%, <500 nM 33%).
In both PC-3 and MCF-7 neo/HER2 xenograft models, GDC-0980 at a dose of 1 mg/kg, exhibits significant antitumor activity by causing tumor growth delay. Furthermore, GDC-0980 results in tumor stasis or regressions at the maximum tolerated dose of 7.5 mg/kg. In mice, intravenous GDC-0980 administration at 1 mg/kg leads to low clearance (Cl
p: 9.2 mL/min/kg, V
ss: 1.7 L/kg). While, oral administration at 5 mg/kg in 80% PEG400 and at 50 mg/kg as a crystalline suspension in 0.5% methylcellulose/0.2% Tween-80 also results in favorable pharmacokinetic parameters.
GDC-0980 (RG7422) is a potent, selective, and orally available inhibitor of PI3Kα, β, δ, γ and mTOR.
Apitolisib (GDC-0980, RG7422, GNE 390)是一种有效的,I型PI3K抑制剂,作用于PI3Kα/β/δ/γ,无细胞试验中IC50分别为5 nM/27 nM/7 nM/14 nM,也是mTOR抑制剂,无细胞试验中Ki为17 nM,比作用于其他PIKK家族激酶选择性高。Apitolisib 在胰腺癌细胞中可同时激活自噬与凋亡。Phase 2。
Target | Value |
p110α
(Cell-free assay)
|
5 nM
|
p110δ
(Cell-free assay)
|
7 nM
|
p110γ
(Cell-free assay)
|
14 nM
|
mTOR
(Cell-free assay)
|
17 nM(Ki app)
|
p110β
(Cell-free assay)
|
27 nM
|
GDC-0980对I类PI3K和mTOR激酶比对其他大多数激酶表现出有效的选择性抑制作用,对mTOR的K
i
为17 nM,对PI3Kα,β,δ,和γ的IC50 分别为5 nM,27 nM,7 nM,和14 nM。在体外,GDC-0980显著抑制PC3和MCF7细胞的细胞增殖,IC50分别为307 nM和255 nM。一项最近的研究表明,GDC-0980通过抑制细胞周期进程,并诱导细胞凋亡降低癌细胞活性,在前列腺癌(IC50 < 200 nM 50%,<500 nM 100%),乳腺癌(IC50 <200 nM 37%,<500 nM 78%) 和NSCLC(IC50 <200 nM 29%,<500 nM 88%)中具有最大效能,在胰腺癌(IC50 <200 nM 13%,<500 nM 67%) 和黑色素瘤细胞系(IC50 <200 nM 0%,<500 nM 33%)中效能较低。
在PC-3和MCF-7 neo/HER2异种移植模型中,GDC-0980在1 mg/kg剂量下,通过引起肿瘤生长延迟,表现出显著的抗肿瘤活性。此外,GDC-0980导致肿瘤郁积或退化,最大耐受剂量为7.5 mg/kg。在小鼠体内,1 mg/kg GDC-0980静脉内给药导致低清除率(Cl
p
: 9.2 mL/min/kg,V
ss
: 1.7 L/kg)。同时,以5 mg/kg的80% PEG400溶液,或50 mg/kg在0.5%甲基纤维素/0.2% Tween-80中以晶体悬浮液口服给药,具有良好的药代动力学参数。
(S)-1-[4-[[2-(2-氨基嘧啶-5-基)-7-甲基-4-(吗啉-4-基)噻吩并[3,2-D]嘧啶-6-基]甲基]哌嗪-1-基]-2-羟基丙-1-酮
上下游产品信息
上游原料
下游产品